<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
<url>
<loc>https://pl.prisysbiotech.com/</loc>
<image:image>
<image:title>Nie  -  Człowiek  Prymas  Badania  Platforma  &amp;  CRO | PRYSY  Biotechnologia</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/logo.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/</loc>
<image:image>
<image:title>Farmakologia NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/biosafety-research/</loc>
<image:image>
<image:title>Badania bezpieczeństwa biologicznego</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/p202303211456214933321.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/</loc>
<image:image>
<image:title>PK PD ADME</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/p202303211449418813566.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/</loc>
<image:image>
<image:title>Badania tłumaczeń</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/p202303211454114300368.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/safety-evaluation/</loc>
<image:image>
<image:title>Ocena bezpieczeństwa</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/p202303211451568197109.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/safety-evaluation/single-dose-repeated-dose-toxicity-testing.html</loc>
<image:image>
<image:title>Single-dose &amp; Repeated Dose Toxicity Testing</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/single-dose-repeated-dose-toxicity-testinga0b95.jpg</image:loc>
</image:image>
<image:image>
<image:title>Single-dose &amp; Repeated Dose Toxicity Testing</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/single-dose-repeated-dose-toxicity-testinga0b95.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/non-human-primate.html</loc>
<image:image>
<image:title>Non-Human Primate (NHP)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
<image:image>
<image:title>Non-Human Primate (NHP)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/what-is-a-nhp-study.html</loc>
<image:image>
<image:title>What Is A NHP Study</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/what-is-a-nhp-study7f0f9.jpg</image:loc>
</image:image>
<image:image>
<image:title>What Is A NHP Study</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/what-is-a-nhp-study7f0f9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/the-nhp-pharmacology-of-prisys.html</loc>
<image:image>
<image:title>The NHP Pharmacology Of Prisys</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/the-nhp-pharmacology-of-prisysb465a.jpg</image:loc>
</image:image>
<image:image>
<image:title>The NHP Pharmacology Of Prisys</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/the-nhp-pharmacology-of-prisysb465a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/toxicokinetics.html</loc>
<image:image>
<image:title>Toxicokinetics</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/toxicokinetics7dc92.png</image:loc>
</image:image>
<image:image>
<image:title>Toxicokinetics</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/toxicokinetics7dc92.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/non-human-primate-model-renal-ischemia.html</loc>
<image:image>
<image:title>Non-Human Primate Model Renal Ischemia Reperfusion Injury (AKI To CKD Transition)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/small/non-human-primate-model-renal-ischemia7ddb4a21-f360-4251-a51c-3cdb367eb3ad.jpg</image:loc>
</image:image>
<image:image>
<image:title>Non-Human Primate Model Renal Ischemia Reperfusion Injury (AKI To CKD Transition)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/non-human-primate-model-renal-ischemia7ddb4a21-f360-4251-a51c-3cdb367eb3ad.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/nhp-asthma-atopic-dermatitis-model.html</loc>
<image:image>
<image:title>NHP Asthma/atopic Dermatitis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/nhp-asthma-atopic-dermatitis-model85f50.png</image:loc>
</image:image>
<image:image>
<image:title>NHP Asthma/atopic Dermatitis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/nhp-asthma-atopic-dermatitis-model85f50.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/nhpresources.html</loc>
<image:image>
<image:title>NHP Resources</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/nhpresources90325.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Resources</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/nhpresources90325.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/biosafety-research/biosafetyresearch.html</loc>
<image:image>
<image:title>Biosafety Research</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/biosafetyresearchcd745.jpg</image:loc>
</image:image>
<image:image>
<image:title>Biosafety Research</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/biosafetyresearchcd745.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/heart-failure-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>NHP Acute Myocardial Infarction (AMI) Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/heart-failure-nonhuman-primates-disease-modela7712.png</image:loc>
</image:image>
<image:image>
<image:title>NHP Acute Myocardial Infarction (AMI) Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/heart-failure-nonhuman-primates-disease-modela7712.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/glaucoma-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Glaucoma Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/glaucoma-nonhuman-primates-disease-model1d4d5.png</image:loc>
</image:image>
<image:image>
<image:title>Glaucoma Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/glaucoma-nonhuman-primates-disease-model1d4d5.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/coagulation-hemostasis-nonhuman-primates.html</loc>
<image:image>
<image:title>Coagulation/Hemostasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/small/coagulation-hemostasis-nonhuman-primates63c5ab02-c0b4-4eb9-b521-9658b5017498.jpg</image:loc>
</image:image>
<image:image>
<image:title>Coagulation/Hemostasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/coagulation-hemostasis-nonhuman-primates63c5ab02-c0b4-4eb9-b521-9658b5017498.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/psoriasis-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Psoriasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/psoriasis-nonhuman-primates-disease-model6e94c.jpg</image:loc>
</image:image>
<image:image>
<image:title>Psoriasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/psoriasis-nonhuman-primates-disease-model6e94c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/hemophilia-a-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Hemophilia A Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/small/hemophilia-a-nonhuman-primates-disease-model4c747716-98c5-4ef0-a508-55e7790a46ff.jpg</image:loc>
</image:image>
<image:image>
<image:title>Hemophilia A Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/hemophilia-a-nonhuman-primates-disease-model4c747716-98c5-4ef0-a508-55e7790a46ff.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/safety-evaluation/new-and-modified-applications.html</loc>
<image:image>
<image:title>New And Modified Applications</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/new-and-modified-applicationsde315.png</image:loc>
</image:image>
<image:image>
<image:title>New And Modified Applications</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/new-and-modified-applicationsde315.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/nhp-non-alcoholic-steatohepatitis-nash-model.html</loc>
<image:image>
<image:title>NHP Non-Alcoholic Steatohepatitis (NASH) Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/nhp-non-alcoholic-steatohepatitis-nash-modelbd73a.png</image:loc>
</image:image>
<image:image>
<image:title>NHP Non-Alcoholic Steatohepatitis (NASH) Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/nhp-non-alcoholic-steatohepatitis-nash-modelbd73a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/safety-evaluation/toxicology.html</loc>
<image:image>
<image:title>Toxicology</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/toxicologycdb96.jpg</image:loc>
</image:image>
<image:image>
<image:title>Toxicology</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/toxicologycdb96.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/delayed-type-hypersensitivity-dth-nonhuman.html</loc>
<image:image>
<image:title>Delayed-type Hypersensitivity (DTH) Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/delayed-type-hypersensitivity-dth-nonhuman90003.jpg</image:loc>
</image:image>
<image:image>
<image:title>Delayed-type Hypersensitivity (DTH) Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/delayed-type-hypersensitivity-dth-nonhuman90003.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/pharmacokinetics.html</loc>
<image:image>
<image:title>Pharmacokinetics</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/pharmacokinetics6a507.png</image:loc>
</image:image>
<image:image>
<image:title>Pharmacokinetics</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/pharmacokinetics6a507.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/tdar-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>T Cell Dependent Antibody Response(TDAR) Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/tdar-nonhuman-primates-disease-modelae31c.jpg</image:loc>
</image:image>
<image:image>
<image:title>T Cell Dependent Antibody Response(TDAR) Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/tdar-nonhuman-primates-disease-modelae31c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/adme.html</loc>
<image:image>
<image:title>ADME</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/adme55f5d.jpg</image:loc>
</image:image>
<image:image>
<image:title>ADME</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/adme55f5d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/embolism-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Pulmonary Artery Hypertension/Embolism Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/embolism-nonhuman-primates-disease-model4e2cf.png</image:loc>
</image:image>
<image:image>
<image:title>Pulmonary Artery Hypertension/Embolism Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/embolism-nonhuman-primates-disease-model4e2cf.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/neuropathic-pain-nhp-model.html</loc>
<image:image>
<image:title>Neuropathic Pain Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/neuropathic-pain-nhp-model48d12.png</image:loc>
</image:image>
<image:image>
<image:title>Neuropathic Pain Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/neuropathic-pain-nhp-model48d12.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/myopia-hyperopia-nhp-model.html</loc>
<image:image>
<image:title>Myopia Hyperopia Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/myopia-hyperopia-nhp-model745fb.png</image:loc>
</image:image>
<image:image>
<image:title>Myopia Hyperopia Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/myopia-hyperopia-nhp-model745fb.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/pharmacodynamics.html</loc>
<image:image>
<image:title>Pharmacodynamics</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/pharmacodynamics620d3.jpg</image:loc>
</image:image>
<image:image>
<image:title>Pharmacodynamics</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/pharmacodynamics620d3.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/nhp-chronic-obstructive-pulmonary-disease.html</loc>
<image:image>
<image:title>NHP Chronic Obstructive Pulmonary Disease (COPD) Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/nhp-chronic-obstructive-pulmonary-disease1524e.png</image:loc>
</image:image>
<image:image>
<image:title>NHP Chronic Obstructive Pulmonary Disease (COPD) Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/nhp-chronic-obstructive-pulmonary-disease1524e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/translational-studies.html</loc>
<image:image>
<image:title>Translational Studies</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/translational-studies5e517.png</image:loc>
</image:image>
<image:image>
<image:title>Translational Studies</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/translational-studies5e517.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/inflammatory-bowel-nhp-disease-model.html</loc>
<image:image>
<image:title>Inflammatory Bowel Disease Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/inflammatory-bowel-nhp-disease-modela21ae.png</image:loc>
</image:image>
<image:image>
<image:title>Inflammatory Bowel Disease Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/inflammatory-bowel-nhp-disease-modela21ae.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/rheumatoid-arthritis-nhp-model.html</loc>
<image:image>
<image:title>Rheumatoid Arthritis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/rheumatoid-arthritis-nhp-model438fa.jpg</image:loc>
</image:image>
<image:image>
<image:title>Rheumatoid Arthritis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/rheumatoid-arthritis-nhp-model438fa.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/multiple-sclerosis-nhp-model.html</loc>
<image:image>
<image:title>Multiple Sclerosis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/multiple-sclerosis-nhp-modelac9f75fb-b6ef-46d4-867c-1ad7b769490b.jpg</image:loc>
</image:image>
<image:image>
<image:title>Multiple Sclerosis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/multiple-sclerosis-nhp-modelac9f75fb-b6ef-46d4-867c-1ad7b769490b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/uveitis-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Uveitis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/uveitis-nonhuman-primates-disease-modele962a.png</image:loc>
</image:image>
<image:image>
<image:title>Uveitis Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/uveitis-nonhuman-primates-disease-modele962a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/nhp-monkey-disease-models.html</loc>
<image:image>
<image:title>NHP(monkey) Disease Models</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-monkey-disease-models0f6a0.png</image:loc>
</image:image>
<image:image>
<image:title>NHP(monkey) Disease Models</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-monkey-disease-models0f6a0.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/amd-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>AMD Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/amd-nonhuman-primates-disease-model78627.png</image:loc>
</image:image>
<image:image>
<image:title>AMD Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/amd-nonhuman-primates-disease-model78627.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/safety-evaluation/immunotoxicity.html</loc>
<image:image>
<image:title>Immunotoxicity Testing and NHP Drug Safety Evaluation</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/immunotoxicity35901.jpg</image:loc>
</image:image>
<image:image>
<image:title>Immunotoxicity Testing and NHP Drug Safety Evaluation</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/immunotoxicity35901.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/mcao-nhp-model.html</loc>
<image:image>
<image:title>Middle Cerebral Artery Occlusion (MCAO) NHP Model Of Stoke &amp; Brain Ischemia</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/mcao-nhp-model0cf8cbb0-48b5-473b-b725-fd749c9c69ca.jpg</image:loc>
</image:image>
<image:image>
<image:title>Middle Cerebral Artery Occlusion (MCAO) NHP Model Of Stoke &amp; Brain Ischemia</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/mcao-nhp-model0cf8cbb0-48b5-473b-b725-fd749c9c69ca.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/safety-evaluation/dose-range-finding-test.html</loc>
<image:image>
<image:title>Dose Range Finding Test</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/dose-range-finding-test1c040.png</image:loc>
</image:image>
<image:image>
<image:title>Dose Range Finding Test</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/dose-range-finding-test1c040.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/nhp-lung-fibrosis-model.html</loc>
<image:image>
<image:title>NHP Lung Fibrosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-lung-fibrosis-model25cd4.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Lung Fibrosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-lung-fibrosis-model25cd4.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/epilepsy-nhp-model.html</loc>
<image:image>
<image:title>Epilepsy Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/epilepsy-nhp-model4f142.jpg</image:loc>
</image:image>
<image:image>
<image:title>Epilepsy Nonhuman Primates Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/epilepsy-nhp-model4f142.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/clearpoint/clearpoint-navigation-for-cns-research.html</loc>
<image:image>
<image:title>ClearPoint Navigation For CNS Research</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/clearpoint-navigation-for-cns-researchf4cb9.jpg</image:loc>
</image:image>
<image:image>
<image:title>ClearPoint Navigation For CNS Research</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/clearpoint-navigation-for-cns-researchf4cb9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/ai-based-nhp-behavior-analysis-system.html</loc>
<image:image>
<image:title>AI-based NHP Behavior Analysis System</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/ai-based-nhp-behavior-analysis-systema5d80.png</image:loc>
</image:image>
<image:image>
<image:title>AI-based NHP Behavior Analysis System</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/ai-based-nhp-behavior-analysis-systema5d80.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/parkinson-s-disease-model.html</loc>
<image:image>
<image:title>Parkinson&#39;s Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/parkinson-s-disease-model9ce85.jpg</image:loc>
</image:image>
<image:image>
<image:title>Parkinson&#39;s Disease Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/parkinson-s-disease-model9ce85.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/clinical-imaging.html</loc>
<image:image>
<image:title>Obrazowanie kliniczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/clinical-imaging585d0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Obrazowanie kliniczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/clinical-imaging585d0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/small/clinical-imagingb514bd15-133f-4e9b-a75a-0e1cbbc1f4f0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/clinical-imagingb514bd15-133f-4e9b-a75a-0e1cbbc1f4f0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/small/clinical-imagingb9ae57aa-6754-41ce-822c-46e3f1c3d84a.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/clinical-imagingb9ae57aa-6754-41ce-822c-46e3f1c3d84a.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/small/clinical-imaginga1e6f856-06fb-4365-aa1c-53949acb37af.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/clinical-imaginga1e6f856-06fb-4365-aa1c-53949acb37af.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/small/clinical-imagingb127b97f-7b00-4335-b905-64e36f57247d.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202439406/clinical-imagingb127b97f-7b00-4335-b905-64e36f57247d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/hyperlipoidemia-model.html</loc>
<image:image>
<image:title>Hyperlipoidemia Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/hyperlipoidemia-modeldc1b0.png</image:loc>
</image:image>
<image:image>
<image:title>Hyperlipoidemia Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/hyperlipoidemia-modeldc1b0.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/type-2-diabetes-mellitus-model.html</loc>
<image:image>
<image:title>Model cukrzycy typu 2</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/type-2-diabetes-mellitus-model5981d.png</image:loc>
</image:image>
<image:image>
<image:title>Model cukrzycy typu 2</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/type-2-diabetes-mellitus-model5981d.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/type-1-diabetes-mellitus-model.html</loc>
<image:image>
<image:title>Type 1 Diabetes Mellitus Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/type-1-diabetes-mellitus-modelbc16f.png</image:loc>
</image:image>
<image:image>
<image:title>Type 1 Diabetes Mellitus Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/type-1-diabetes-mellitus-modelbc16f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/immunosuppression-model.html</loc>
<image:image>
<image:title>Immunosuppression Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/immunosuppression-model9e95e.jpg</image:loc>
</image:image>
<image:image>
<image:title>Immunosuppression Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/immunosuppression-model9e95e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/renal-fibrosis-model.html</loc>
<image:image>
<image:title>Renal Fibrosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/renal-fibrosis-modelb87a4.jpg</image:loc>
</image:image>
<image:image>
<image:title>Renal Fibrosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/renal-fibrosis-modelb87a4.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/a-v-shunt-model.html</loc>
<image:image>
<image:title>A-V Shunt Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/a-v-shunt-modelef93d.jpg</image:loc>
</image:image>
<image:image>
<image:title>A-V Shunt Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/a-v-shunt-modelef93d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/endometriosis-model.html</loc>
<image:image>
<image:title>Endometriosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/endometriosis-modeldd994.png</image:loc>
</image:image>
<image:image>
<image:title>Endometriosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/endometriosis-modeldd994.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/clearpoint/convection-enhanced-delivery-ced-technology.html</loc>
<image:image>
<image:title>Convection-Enhanced Delivery (CED) Technology</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/convection-enhanced-delivery-ced-technology7e74b.png</image:loc>
</image:image>
<image:image>
<image:title>Convection-Enhanced Delivery (CED) Technology</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/convection-enhanced-delivery-ced-technology7e74b.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/clearpoint/nhp-neuroscience.html</loc>
<image:image>
<image:title>NHP Neuroscience</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-neuroscience94a5c.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Neuroscience</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-neuroscience94a5c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/atopic-dermatitis-nhp-model.html</loc>
<image:image>
<image:title>Atopic Dermatitis NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/atopic-dermatitis-nhp-model0fc1f.jpg</image:loc>
</image:image>
<image:image>
<image:title>Atopic Dermatitis NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/atopic-dermatitis-nhp-model0fc1f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/pruritus-nhp-model.html</loc>
<image:image>
<image:title>Pruritus NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/pruritus-nhp-modelfcbdb.jpg</image:loc>
</image:image>
<image:image>
<image:title>Pruritus NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/pruritus-nhp-modelfcbdb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/inflammatory-bowel-disease-ibd-nhp-model.html</loc>
<image:image>
<image:title>Inflammatory Bowel Disease IBD NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/inflammatory-bowel-disease-ibd-nhp-model048b6.png</image:loc>
</image:image>
<image:image>
<image:title>Inflammatory Bowel Disease IBD NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/inflammatory-bowel-disease-ibd-nhp-model048b6.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/targeted-organ-drug-delivery-platform-in-nhp.html</loc>
<image:image>
<image:title>Targeted Organ Drug Delivery Platform in NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/targeted-organ-drug-delivery-platform-in-nhpe13f9.png</image:loc>
</image:image>
<image:image>
<image:title>Targeted Organ Drug Delivery Platform in NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/targeted-organ-drug-delivery-platform-in-nhpe13f9.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/aav-synuclein-overexpression-nhp-model.html</loc>
<image:image>
<image:title>AAV-α-Synuclein Overexpression NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/aav-synuclein-overexpression-nhp-model93460.jpg</image:loc>
</image:image>
<image:image>
<image:title>AAV-α-Synuclein Overexpression NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/aav-synuclein-overexpression-nhp-model93460.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/heart-failure-nhp-model.html</loc>
<image:image>
<image:title>Heart Failure NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/heart-failure-nhp-model8c759.jpg</image:loc>
</image:image>
<image:image>
<image:title>Heart Failure NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/heart-failure-nhp-model8c759.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/acute-lung-inflammation-ali-nhp-model.html</loc>
<image:image>
<image:title>Acute Lung Inflammation (ALI) NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/acute-lung-inflammation-ali-nhp-modelcce6e.png</image:loc>
</image:image>
<image:image>
<image:title>Acute Lung Inflammation (ALI) NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/acute-lung-inflammation-ali-nhp-modelcce6e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/nose-to-brain-drug-delivery.html</loc>
<image:image>
<image:title>Nose-to-Brain Drug Delivery</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/nose-to-brain-drug-delivery15a9e.jpg</image:loc>
</image:image>
<image:image>
<image:title>Nose-to-Brain Drug Delivery</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nose-to-brain-drug-delivery15a9e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/acute-hemorrhagic-shock-model-nhp-model.html</loc>
<image:image>
<image:title>Acute Hemorrhagic Shock Model NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/acute-hemorrhagic-shock-model-nhp-model5b827.png</image:loc>
</image:image>
<image:image>
<image:title>Acute Hemorrhagic Shock Model NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/acute-hemorrhagic-shock-model-nhp-model5b827.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/retinitis-pigmentosa-rp-nhp-model.html</loc>
<image:image>
<image:title>Retinitis Pigmentosa (RP) NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/retinitis-pigmentosa-rp-nhp-model49f0f.png</image:loc>
</image:image>
<image:image>
<image:title>Retinitis Pigmentosa (RP) NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/retinitis-pigmentosa-rp-nhp-model49f0f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/liver-fibrosis-model.html</loc>
<image:image>
<image:title>Liver Fibrosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/liver-fibrosis-modelc2688.png</image:loc>
</image:image>
<image:image>
<image:title>Liver Fibrosis Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/liver-fibrosis-modelc2688.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/biodistribution-imaging-service.html</loc>
<image:image>
<image:title>Biodistribution Imaging Service</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/biodistribution-imaging-serviceabec3.png</image:loc>
</image:image>
<image:image>
<image:title>Biodistribution Imaging Service</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/biodistribution-imaging-serviceabec3.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/translation-research/dsa-guided-interventional-platform.html</loc>
<image:image>
<image:title>DSA-Guided Interventional Platform For NHP Research | Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/dsa-guided-interventional-platformb8fb1.png</image:loc>
</image:image>
<image:image>
<image:title>DSA-Guided Interventional Platform For NHP Research | Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/dsa-guided-interventional-platformb8fb1.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/nhp-intracerebral-injection-icm-services.html</loc>
<image:image>
<image:title>NHP Intracerebral (ICM) Injection| Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/nhp-intracerebral-injection-icm-servicesbbf15.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Intracerebral (ICM) Injection| Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-intracerebral-injection-icm-servicesbbf15.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/nhp-intrathecal-dosing-csf-sampling.html</loc>
<image:image>
<image:title>NHP Intrathecal (IT) Injection &amp; CSF Sampling Services | Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/nhp-intrathecal-dosing-csf-samplingb3e80.png</image:loc>
</image:image>
<image:image>
<image:title>NHP Intrathecal (IT) Injection &amp; CSF Sampling Services | Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-intrathecal-dosing-csf-samplingb3e80.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/nhp-pharmacology/nhp-focal-segmental-glomerulosclerosis-fsgs.html</loc>
<image:image>
<image:title>Focal Segmental Glomerulosclerosis (FSGS) NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/small/nhp-focal-segmental-glomerulosclerosis-fsgsd2851.jpg</image:loc>
</image:image>
<image:image>
<image:title>Focal Segmental Glomerulosclerosis (FSGS) NHP Model</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/page/nhp-focal-segmental-glomerulosclerosis-fsgsd2851.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/pk-pd-adme/nhp-intracerebroventricular-icv-injection.html</loc>
<image:image>
<image:title>NHP Intracerebroventricular (ICV) Injection | Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/small/nhp-intracerebroventricular-icv-injectionccb4c.png</image:loc>
</image:image>
<image:image>
<image:title>NHP Intracerebroventricular (ICV) Injection | Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/nhp-intracerebroventricular-icv-injectionccb4c.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/molecular-imaging-in-nhp-model-webinar-18003160318829568.html</loc>
<image:image>
<image:title>Obrazowanie molekularne w modelach NHP do opracowywania leków o translacji</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260817131455786a8.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-behavioratlas-3d-behavioral-tracking-17968936582816768.html</loc>
<image:image>
<image:title>Seminarium internetowe NHP BehaviorAtlas|Śledzenie zachowań 3D NHP na potrzeby opracowywania leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260706130958536b1.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/2025-recap-how-prisys-is-redefining-translati-17724203354989568.html</loc>
<image:image>
<image:title>Podsumowanie roku 2025: Jak Prisys na nowo definiuje niezawodność translacyjną w badaniach nad NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260115105444c1b0c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-based-pharmacology-and-pharmacodynamic-17554206996734976.html</loc>
<image:image>
<image:title>NHP - Farmakologia i usługi farmakodynamiczne|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/meet-prisys-biotech-at-upcoming-eu-roadshow-17530078440678400.html</loc>
<image:image>
<image:title>Poznaj Prisys Biotech na nadchodzącym UE Roadshow: wrzesień 2025</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025082013335410dba.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-2025-mid-year-review-17447039481750528.html</loc>
<image:image>
<image:title>Prisys Biotech-2025 w połowie roku przegląd</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/meet-prisys-in-2025-us-roadshow-17245402345563136.html</loc>
<image:image>
<image:title>Poznaj Prisys w nadchodzącym amerykańskim drogom w marcu 2025 r.</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-annual-report-2024-advancing-nhp-model-84033129.html</loc>
<image:image>
<image:title>Raport roczny PRISYS 2024: Udoskonalanie modeli NHP i badania przedkliniczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20241204135917ca94f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-2024-q2-newsletter-77715759.html</loc>
<image:image>
<image:title>Biuletyn Prisys Biotech – 2. kwartał 2024 r. – Udoskonalone przedkliniczne prace badawczo-rozwojowe w zakresie terapii OUN dzięki modelom reaktywności krzyżowej PRISYS</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20240520124055bc2de.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/animal-models-succeed-or-fail-in-drug-dev-18028065369990144.html</loc>
<image:image>
<image:title>Dlaczego modele zwierzęce odnoszą sukcesy lub ponoszą porażki w opracowywaniu leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/quantitative-pet-target-engagement-in-nhps-for-18021143159497728.html</loc>
<image:image>
<image:title>Ilościowe zaangażowanie docelowe PET w NHP w przypadku leków na ośrodkowy układ nerwowy</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608261535298f0fc.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/3d-ai-tracking-nhp-behavior-18015320353481728.html</loc>
<image:image>
<image:title>Od wideo do danych: śledzenie 3D AI zachowań NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/p2026082115534501025.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pet-biodistribution-nhp-studies-18015416238531584.html</loc>
<image:image>
<image:title>Obrazowanie biodystrybucji PET u-naczelnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608191309007190a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pbpk-vs-compartmental-models-drug-development-18003160417838080.html</loc>
<image:image>
<image:title>PBPK vs. Modele przedziałowe: dlaczego PBPK ma znaczenie</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260814103950d26c5.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/webinar-recap-digital-behavioral-phenotyping-17993109805229056.html</loc>
<image:image>
<image:title>Podsumowanie seminarium internetowego: Postęp w badaniach nad NHP w zakresie translacji poprzez cyfrowe fenotypowanie behawioralne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260807130040f7d24.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pk-biomarkers-preclinical-drug-development-17990394976723968.html</loc>
<image:image>
<image:title>Biomarkery PK w przedklinicznym opracowywaniu leków|Ekspozycja – reakcja i PK/PD</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260805152832759f2.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/behavior-in-rhesus-17984784245646336.html</loc>
<image:image>
<image:title>Spontaniczne samo-szkodliwe zachowanie u makaków rezusów: translacyjny model NHP na potrzeby opracowywania leków neuropsychiatrycznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260731163230fd87d.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/midd-and-nhp-efficacy-models-in-drug-17984774877258752.html</loc>
<image:image>
<image:title>Modele skuteczności MIDD i NHP w opracowywaniu leków o translacji</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026073013213937533.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/markerless-3d-nhp-behavior-analysis-17976090156966912.html</loc>
<image:image>
<image:title>AI-Analiza behawioralna 3D NHP oparta na sztucznej inteligencji|Bezmarkerowe fenotypowanie behawioralne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260723161948c057f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/webinar-nhp-behavioratlas-17976122198041600.html</loc>
<image:image>
<image:title>Globalne seminarium internetowe|Ilościowe określanie złożonych zachowań NHP: wprowadzenie do atlasu zachowań NHP do-dokładnego fenotypowania behawioralnego 3D</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260721164252b91dc.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/ai-nhp-behavioral-analysis-17968931637306368.html</loc>
<image:image>
<image:title>AI-Analiza behawioralna oparta na NHP na potrzeby przedklinicznego opracowywania leków|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202607171631204cfce.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/when-to-introduce-nhp-studies-autoimmune-drug-17976074717324288.html</loc>
<image:image>
<image:title>Kiedy wprowadzić badania NHP w zakresie opracowywania leków autoimmunologicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026071314114600533.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-ibd-model-chronic-enterocolitis-17976073786532864.html</loc>
<image:image>
<image:title>Modele NHP IBD: czego przewlekłe zapalenie jelit u makaków rezusów uczy nas o translacyjnym zapaleniu jelit</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260710141850796f6.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-aav-gene-therapy-model-mri-guided-ced-17976112506594304.html</loc>
<image:image>
<image:title>MRI-Sterowane dostarczanie AAV do modeli mózgu NHP na potrzeby terapii genowej OUN</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202607071035506b1ed.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/why-positive-control-drugs-matter-in-autoimmun-17976076065793024.html</loc>
<image:image>
<image:title>Dlaczego leki kontroli pozytywnej mają znaczenie w modelach chorób autoimmunologicznych|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202607011605210dd31.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/baseline-ada-screening-washed-out-monkeys-17976087468844032.html</loc>
<image:image>
<image:title>Wyjściowe badanie przesiewowe ADA u wypłukanych-małp do przedklinicznych badań biologicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026062914295408abb.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pain-mechanisms-the-uvb-sunburn-model-17968931288785920.html</loc>
<image:image>
<image:title>Mechanizmy bólu: model oparzeń słonecznych UVB jest niezbędnym narzędziem translacyjnym</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202606261052354a6de.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-models-of-maternal-high-fat-diet-and-child-17968951883310080.html</loc>
<image:image>
<image:title>Modele NHP dotyczące diety wysokotłuszczowej matki i programowania otyłości u dzieci</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260626101823325bd.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/clinical-pathology-interpretation-dogs-nhp-17942096294257664.html</loc>
<image:image>
<image:title>Interpretacja patologii klinicznej u psów i naczelnych innych niż ludzie w badaniach przedklinicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260623143229ac184.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/molecular-imaging-biomarkers-advancing-transl-17942096286557184.html</loc>
<image:image>
<image:title>Biomarkery obrazowania molekularnego: postęp w badaniach translacyjnych i opracowywaniu leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202606181451278625b.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonlinear-pharmacokinetics-explained-17942096285967360.html</loc>
<image:image>
<image:title>Co to jest farmakokinetyka nieliniowa? Mechanizmy, cechy i implikacje dla rozwoju leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260616141042be995.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-molecular-imaging-translational-pet-studie-17942097631568896.html</loc>
<image:image>
<image:title>Dlaczego obrazowanie molekularne NHP ma kluczowe znaczenie w translacyjnych badaniach PET</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202606121112387f111.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/what-is-molecular-imaging-drug-development-17942097376502784.html</loc>
<image:image>
<image:title>Co to jest obrazowanie molekularne i dlaczego jest ważne w opracowywaniu leków?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026061013321190d5a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-radionuclide-biodistribution-17942098245542912.html</loc>
<image:image>
<image:title>Badania biodystrybucji radionuklidów NHP: obrazowanie molekularne na potrzeby opracowywania leków o translacji</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026060515134174d47.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-heart-failure-model-17942095990334464.html</loc>
<image:image>
<image:title>Model niewydolności serca NHP wspiera badania translacyjne nad terapią genową przywracającą telomery</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260602142703b954a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/dsa-cta-cardiovascular-drug-safety-imaging-17942096056624128.html</loc>
<image:image>
<image:title>Jak obrazowanie DSA i CTA poprawia ocenę bezpieczeństwa leków dla układu sercowo-naczyniowego</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026052913380640f74.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-av-shunt-thrombosis-model-17942096952714240.html</loc>
<image:image>
<image:title>Model zakrzepicy tętniczo-żylnej NHP u małp Cynomolgus do oceny translacyjnego leku przeciwzakrzepowego</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260527103349ad81a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pk-data-as-translational-biomarker-17888378900390912.html</loc>
<image:image>
<image:title>Dane farmakokinetyczne jako biomarker translacyjny</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202605211329439d160.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-human-primate-models-of-pulmonary-fibrosis-17888378888561664.html</loc>
<image:image>
<image:title>Modele zwłóknienia płuc nie{0}}ludzkich naczelnych: większa dokładność translacyjna w opracowywaniu leków na drogi oddechowe</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260515153544ef082.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-models-translational-drug-development-17888378606150656.html</loc>
<image:image>
<image:title>Dlaczego rozwój leków w coraz większym stopniu zależy od modeli NHP|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260514093832593bb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pk-data-as-pharmacodynamic-biomarker-17888378800792576.html</loc>
<image:image>
<image:title>Dane PK jako biomarker farmakodynamiczny: postęp w opracowywaniu leków o translacji poprzez farmakologię ilościową</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202605091519031a196.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-glp-pharmacology-data-integrity-17854339747210240.html</loc>
<image:image>
<image:title>Badania farmakologiczne inne niż-GLP do celów przedkładania przepisów: integralność danych i wymagania laboratoryjne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260424104846a67ea.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonclinical-pharmacokinetics-strategy-17854339698041856.html</loc>
<image:image>
<image:title>Strategiczny projekt nieklinicznych badań farmakokinetycznych: od profilowania ADME do podejmowania decyzji o tłumaczeniu-</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202604201042394eb2f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-av-shunt-thrombosis-model-antibody-safety-17854339703956480.html</loc>
<image:image>
<image:title>NHP AV-Model zakrzepicy z przetoką przetokową do oceny bezpieczeństwa leku|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260417154405f8553.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonlinear-pharmacokinetics-nhp-pkpd-17854339590579200.html</loc>
<image:image>
<image:title>Co to jest farmakokinetyka nieliniowa? Mechanizmy i translacyjna ocena PK|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260414144233849f1.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-supports-ind-approval-of-ux-gip001-17854339623166976.html</loc>
<image:image>
<image:title>Prisys Biotech wspiera zatwierdzenie UX-GIP001 przez IND przez FDA i CDE|Platforma dostarczania CNS NHP</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/157.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/in-vivo-immune-cell-tracking-17854339679249408.html</loc>
<image:image>
<image:title>Śledzenie komórek odpornościowych in vivo i rozwój znaczników PET w modelach NHP|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202604021117547afde.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/dopamine-transporter-pet-imaging-in-nhp-models-17854339547816960.html</loc>
<image:image>
<image:title>Obrazowanie PET transportera dopaminy w modelach NHP|Obrazowanie OUN|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026033113465773e8f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pet-ct-biodistribution-in-nhp-models-for-cns-17854339456574464.html</loc>
<image:image>
<image:title>Biodystrybucja PET/CT w modelach NHP do dostarczania leków do OUN|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202603271731432da82.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/large-animal-radiolabeling-and-in-vivo-imaging-17854339705218048.html</loc>
<image:image>
<image:title>Duża-platforma do radioznakowania zwierząt i obrazowania in vivo na potrzeby opracowywania leków o translacji</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260323111154bf8b7.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/drug-development-reliance-on-nhp-models-17854339478578176.html</loc>
<image:image>
<image:title>Dlaczego rozwój leków w coraz większym stopniu opiera się na modelach NHP: zasadnicza rola naczelnych w medycynie translacyjnej|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260320115823340b4.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/ipf-drug-development-nhp-ct-imaging-pft-17854339702285312.html</loc>
<image:image>
<image:title>Wyzwania i rozwiązania IPF w zakresie rozwoju leków|Modele NHP z obrazowaniem CT i PFT</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026031715015159514.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/ai-markerless-nhp-3d-behavior-analysis-system-17854352475923456.html</loc>
<image:image>
<image:title>System analizy zachowania AI Markerless NHP 3D do badań przedklinicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260313142823bc65b.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/evaluating-dmpk-properties-17854339605767168.html</loc>
<image:image>
<image:title>Ocena właściwości DMPK związków kandydujących we wczesnym odkrywaniu leków|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260310153743383ae.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/mri-guided-cns-delivery-in-nhp-models-17854339534218240.html</loc>
<image:image>
<image:title>MRI-Sterowane dostarczanie do OUN w modelach NHP|Translacyjna platforma IMRI i CED</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202602261246469558e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-cns-biodistribution-studies-intrathecal-17854339448300544.html</loc>
<image:image>
<image:title>Badania biodystrybucji NHP CNS|Dooponowe dostarczanie RNA|PRIYS Biotechnologia</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260214120241d2f33.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/translational-pk-pd-framework-cynomolgus-17854339812549632.html</loc>
<image:image>
<image:title>Translacyjne ramy PK/PD: przewidywanie dawki makaka jawajskiego dla człowieka|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260213142144bd00d.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/emotional-memory-chronic-pain-nhp-models-17724203473675264.html</loc>
<image:image>
<image:title>Kiedy ból staje się wspomnieniem: emocjonalne przyczyny przewlekłego bólu i przewaga modelu NHP|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026012713131077473.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/multi-endpoint-pain-assessment-the-future-17724203358594048.html</loc>
<image:image>
<image:title>Wielo-ocena bólu w punktach końcowych: przyszłość rozwoju leków przeciwbólowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260123153636bce28.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/analgesics-fail-in-preclinical-measure-pain-17724220213142528.html</loc>
<image:image>
<image:title>Dlaczego tak wiele leków przeciwbólowych zawodzi w badaniach przedklinicznych? Odpowiedź kryje się w tym, jak mierzymy ból</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260120155944a4ef1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/blood-sampling-time-point-in-pharmacokinetic-17724220402492416.html</loc>
<image:image>
<image:title>Projekt punktu czasowego pobierania próbek krwi w badaniach farmakokinetycznych (PK)|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026011316592151314.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pk-statistical-analysis-nca-parameters-guide-17724203517928448.html</loc>
<image:image>
<image:title>Statystyki PK: parametry analizy niekompartmentowej (NCA) i zastosowania przedkliniczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260109161837141c9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-human-primate-models-are-critical-cns-17724203386463232.html</loc>
<image:image>
<image:title>Dlaczego modele naczelnych innych niż ludzie- mają kluczowe znaczenie w terapii oligonukleotydami OUN</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260106130909b5b92.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/uric-acid-metabolism-in-humans-vs-monkeys-17724203392246784.html</loc>
<image:image>
<image:title>Metabolizm kwasu moczowego u ludzi i małp: implikacje translacyjne dla rozwoju leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026010416213306463.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-human-primate-mash-associated-liver-fibros-17724203308524544.html</loc>
<image:image>
<image:title>Model MASH innych naczelnych niż-ludzki-powiązany z włóknieniem wątroby|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/p20251226155519da3af.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/imri-guided-brain-drug-delivery-17724203336000512.html</loc>
<image:image>
<image:title>Dlaczego kierowane dostarczanie leków do mózgu metodą IMRI-jest niezbędne do precyzyjnego targetowania w badaniach NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202512231619222564f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/ai-driven-markerless-3d-behavioral-analysis-17674550222382080.html</loc>
<image:image>
<image:title>AI-Bezmarkerowy system analizy behawioralnej NHP 3D|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202512181608129079f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/lps-induced-acute-lung-inflammation-ali-nhp-17674550257263616.html</loc>
<image:image>
<image:title>LPS-Indukowane ostre zapalenie płuc (ALI) Model NHP|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202512161502375ccdb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/hdm-seb-induced-atopic-dermatitis-atd-model-17674550333449216.html</loc>
<image:image>
<image:title>HDM+SEB-Model indukowanego atopowego zapalenia skóry (AtD) u małp Cynomolgus</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251212144449750c1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/one-to-multi-compartment-pk-models-17674550359663616.html</loc>
<image:image>
<image:title>Wyjaśnienie modeli PK z jednym- do wielu-kompartmentów|Farmakokinetyka NHP|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251208140839d8db0.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-to-choose-a-reliable-preclinical-cro-key-17674563477988352.html</loc>
<image:image>
<image:title>Jak wybrać niezawodnego CRO do badań przedklinicznych|Kluczowe kryteria dla firm biotechnologicznych|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251204133731f364a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/translational-car-t-evaluation-in-vitro-17674563312182272.html</loc>
<image:image>
<image:title>Translacyjna ocena CAR-T: wiedza specjalistyczna in vitro i wsparcie w badaniach NHP — Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202512011123451e873.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cns-drug-candidates-in-preclinical-study-17674550231753728.html</loc>
<image:image>
<image:title>Dlaczego ponad 90% kandydatów na leki działające na OUN nie przechodzi badań klinicznych?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202511281410270841e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/parkinsons-disease-preclinical-models-17674550492587009.html</loc>
<image:image>
<image:title>Modele przedkliniczne choroby Parkinsona: przewodnik po wyborze modeli neurotoksyn, modeli genetycznych i NHP|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025112415472074828.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/high-precision-drug-delivery-and-ai-driven-nhp-17674550345556992.html</loc>
<image:image>
<image:title>Platformy translacyjne NHP o-precyzyjnej precyzji i{1}}sterowanej sztuczną inteligencją</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025112108401436404.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/th17-driven-nhp-immunology-models-17625032781063168.html</loc>
<image:image>
<image:title>Modele immunologiczne NHP sterowane Th17|Translacyjne badania autoimmunologiczne w Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251117110751844f3.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/ai-based-nhp-behavioratlas-system-3d-behavi-17625032917902336.html</loc>
<image:image>
<image:title>System-oparty na sztucznej inteligencji NHP BehaviorAtlas®|Platforma analizy behawioralnej 3D|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251114162428314a9.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/rfp-template-for-nhp-studies-17625032706155520.html</loc>
<image:image>
<image:title>Szablon zapytania ofertowego dotyczącego badań NHP|Przyspiesz efektywność badań przedklinicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025111015483953c4b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cold-allodynia-pain-model-in-cynomolgus-monkey-17625032638850048.html</loc>
<image:image>
<image:title>Model bólu zimnej allodynii u małp Cynomolgus|Biotechnologie Prisys</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251107160515acddb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/mri-guided-intracerebral-drug-delivery-17625032862557184.html</loc>
<image:image>
<image:title>MRI-Platforma sterowanego śródmózgowego podawania leku|Badania OUN Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025110514460235db1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-respiratory-disease-models-and-airway-drug-17625033100207104.html</loc>
<image:image>
<image:title>Modele chorób układu oddechowego NHP i platforma dostarczania leków przez drogi oddechowe|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251028164336adaf3.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-renal-biopsy-17625032974492672.html</loc>
<image:image>
<image:title>Platforma biopsji nerek NHP i modele chorób nerek|Prisys Biotech</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/276.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pk-study-targeted-drug-delivery-17625032945067008.html</loc>
<image:image>
<image:title>Badania PK i ukierunkowane dostarczanie leków|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202510171638300dafe.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-ai-based-behavioral-analysis-17625032763778048.html</loc>
<image:image>
<image:title>Platforma badawcza i analiza behawioralna oparta-na sztucznej inteligencji firmy Prisys Biotechnologies</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025101517485012ee9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nasal-to-brain-n2b-delivery-technology-for-c-17625032625562624.html</loc>
<image:image>
<image:title>Technologia dostarczania z nosa-do-mózgu (N2B) do badań OUN|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20251011133522c7c7b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/shr-2004-a-breakthrough-in-vte-prevention-for-17625032559453184.html</loc>
<image:image>
<image:title>SHR-2004: Przełom w zapobieganiu ŻChZZ u pacjentek z rakiem jajnika – historia sukcesu autorstwa Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025101011280623985.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cynomolgus-rhesus-monkey-models-prisys-bio-17538459517559808.html</loc>
<image:image>
<image:title>Modele małp Cynomolgus i Rhesus|Prisys Biotech Przedkliniczny CRO</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/idiopathic-pulmonary-fibrosis-ipf-nhp-model-17530078224327680.html</loc>
<image:image>
<image:title>Idiopatyczne zwłóknienie płuc (IPF) Model NHP|Prisys biotechniczne przedkliniczne cro</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250912151948fd2c4.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cynomolgus-monkey-biodistribution-study-17530078645543936.html</loc>
<image:image>
<image:title>Badania biodystrybucji małp Cynomolgus|Prisys Biotech Przedkliniczny CRO</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202509091635226f118.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-models-for-hematology-and-stroke-17530078849508352.html</loc>
<image:image>
<image:title>Prisys Biotech NHP modele do badań hematologii i udań</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250903101944cac91.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-importance-of-administration-volume-17530078323401728.html</loc>
<image:image>
<image:title>Znaczenie objętości administracji w badaniach przedklinicznych|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202508261427201a2af.gif</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/brain-targeted-drug-delivery-17530078240187392.html</loc>
<image:image>
<image:title>Brain - Ukierunkowane dostarczanie leku|Prisys biotechnologiczne badania przedkliniczne NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202508221539309f4a5.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/adc-drug-development-translational-pk-pd-fra-17530078347961344.html</loc>
<image:image>
<image:title>Rozwój leków ADC|Translacyjne ramy PK/PD w przedklinicznych badaniach NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026062914295408abb.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-pain-models-for-translational-drug-discove-17495139886228480.html</loc>
<image:image>
<image:title>Modele bólu NHP dla translacyjnego odkrywania leków|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250813095806db594.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/serum-vs-plasma-choosing-the-optimal-matrix-17495139820692480.html</loc>
<image:image>
<image:title>Serum vs. Osocze: wybór optymalnej matrycy do bioanalizy przedklinicznej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250805095551af23f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/preclinical-dosing-guidelines-iv-po-volume-17495139842008064.html</loc>
<image:image>
<image:title>Wytyczne dotyczące dawkowania przedklinicznego: objętość IV i PO, PH i osmolarność w celu uzyskania dokładnej PK u zwierząt NHP i innych gatunków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250731153850aa43a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-copd-model-17495139847169024.html</loc>
<image:image>
<image:title>Najlepsze modele badań POChP i doskonałość platformy oddechowej przez Prisys</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250730125053bd455.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-acute-hemorrhage-model-17495139727483904.html</loc>
<image:image>
<image:title>Model ostrego krwotoku NHP: kluczowe narzędzie do przyspieszenia nowego hematologii rozwój leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250722163908bd854.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pruritus-research-il-31-nhp-itch-model-17495139881952256.html</loc>
<image:image>
<image:title>Badania Pruritus: Model NHP indukowany IL-31 Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202504011023488ec4a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/a-guide-to-anti-drug-antibody-ada-assessment-17447040156001280.html</loc>
<image:image>
<image:title>Przewodnik po ocenie-przeciwciał lekowych (ADA).</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/respiratory-therapies-prisys-biotech-s-integr-17447040185263104.html</loc>
<image:image>
<image:title>Terapie oddechowe: zintegrowana platforma NHP firmy Prisys Biotech do badań przedklinicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-pain-models-accelerating-analgesic-drug-d-17447040281912320.html</loc>
<image:image>
<image:title>Modele bólu NHP: Przyspieszenie opracowywania leków przeciwbólowych w Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/p20250704135241befde.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-model-platforms-to-support-drug-developmen-17447039562310656.html</loc>
<image:image>
<image:title>Platformy modelowe NHP do wspierania rozwoju leków w złożonych chorobach</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/key-considerations-for-dosing-volume-17447039445476352.html</loc>
<image:image>
<image:title>Kluczowe kwestie dotyczące objętości dawkowania, PH i formulacji w modelach zwierzęcych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202506260936191360e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/engineered-exosomes-revolutionizing-drug-deli-17447039440315392.html</loc>
<image:image>
<image:title>Zaprojektowane egzosomy: rewolucja w dostarczaniu leków na zaburzenia OUN – przedkliniczne spostrzeżenia Prisys Biotech</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/300.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/guiding-principles-for-animal-species-selectio-17447039530132480.html</loc>
<image:image>
<image:title>Wytyczne dotyczące selekcji gatunków zwierząt w badaniach toksykologicznych leków zawierających kwasy nukleinowe</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-s-advanced-dsa-and-imri-for-hem-17447077258568704.html</loc>
<image:image>
<image:title>Prisys Biotech DSA i IMRI do badań hematologicznych, naczyniowych i chorób nerek</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250610100231b6146.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cynomolgus-monkey-pain-models-17447039355315200.html</loc>
<image:image>
<image:title>Modele bólu małpy Cynomolgus: wspomaganie badań translacyjnych na rzecz przełomowych terapii kanałów jonowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advancing-atopic-dermatitis-research-prisys-b-17447039559312384.html</loc>
<image:image>
<image:title>Postępowanie w Atopic Pisatis Bade</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250530142432192c3.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-s-nhp-atopic-dermatitis-model-f-17447039263532032.html</loc>
<image:image>
<image:title>NHP Prisys Biotech Atopic Model zapalenia skóry do opracowywania leków przeciwprutowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/p20250527155048d3f8c.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/designing-animal-studies-key-considerations-f-17386666660914176.html</loc>
<image:image>
<image:title>Projektowanie badań na zwierzętach: kluczowe czynniki wpływające na sukces badań przedklinicznych</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/300.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/atopic-dermatitis-how-cynomolgus-monkey-model-17386666502136832.html</loc>
<image:image>
<image:title>Atopowe zapalenie skóry: jak modele małp Cynomolgus postępują w precyzji terapeutyki</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025052012503626be2.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/asthma-research-why-non-human-primate-models-17386628957201408.html</loc>
<image:image>
<image:title>Badania nad astmą: dlaczego-modele naczelnych innych niż ludzie odgrywają kluczową rolę w opracowywaniu nowych leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/aso-pharmacokinetics-absorption-17386629168702464.html</loc>
<image:image>
<image:title>Zrozumienie farmakokinetyki oligonukleotydów antysensownych (ASO): kluczowe czynniki wchłaniania i dystrybucji</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-inhalation-studies-for-biologics-prisys-17386629257225216.html</loc>
<image:image>
<image:title>Badania inhalacyjne NHP dla leków biologicznych: specjalistyczne przedkliniczne usługi CRO firmy PRISYS</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/300.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advanced-preclinical-inhalation-studies-techn-17386628995359744.html</loc>
<image:image>
<image:title>Zaawansowane przedkliniczne badania inhalacyjne: możliwości techniczne i wiedza specjalistyczna w Prisys Biotech</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/300.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacokinetics-pk-key-parameters-17386628948321280.html</loc>
<image:image>
<image:title>Zrozumienie farmakokinetyki (PK): kluczowe parametry i zastosowania w opracowywaniu leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025042511302920eb4.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/intracerebroventricular-icv-injection-17386629042906112.html</loc>
<image:image>
<image:title>Wstrzyknięcie do komór mózgowych (ICV): precyzyjne podanie do OUN do badań przedklinicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025042210212390d49.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/intracerebral-icm-injection-precision-targe-17386628928496640.html</loc>
<image:image>
<image:title>Wstrzyknięcie śródmózgowe (ICM): precyzyjne ukierunkowanie w terapii OUN – rozważania przedkliniczne</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/intrathecal-it-injection-a-direct-cns-deliv-17386628940375040.html</loc>
<image:image>
<image:title>Wstrzyknięcie dooponowe (IT): bezpośrednia droga podania do OUN w terapiach zaawansowanych – rozważania przedkliniczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advancing-parkinson-s-disease-research-with-th-17386628867187712.html</loc>
<image:image>
<image:title>Postęp w badaniach nad chorobą Parkinsona za pomocą modelu NHP</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/300.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/preclinical-pk-pd-studies-nhp-models-17386629202715648.html</loc>
<image:image>
<image:title>Przedkliniczne badania PK/PD i modele NHP do opracowywania leków|Prisys Biotech</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/300.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/targeting-interleukin-31-autoimmune-disease-17302340964819968.html</loc>
<image:image>
<image:title>Celowanie w interleukinę-31 (IL-31): nowatorskie podejście do opracowywania leków na choroby autoimmunologiczne – modele NHP Prisys Biotech do badań przedklinicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202504011023488ec4a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonclinical-immunotoxicity-assessment-strateg-17301407372436480.html</loc>
<image:image>
<image:title>Niekliniczna ocena immunotoksyczności: strategia, kluczowe rozważania i wybór metody</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/232.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/microbial-testing-and-its-impact-on-nhp-17301407080932352.html</loc>
<image:image>
<image:title>Testy mikrobiologiczne i ich wpływ na-naczelnych innych niż ludzie w przedklinicznych badaniach DMPK</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cynomolgus-monkey-endometriosis-model-17301407239316480.html</loc>
<image:image>
<image:title>Model endometriozy małpy Cynomolgus do postępów w badaniach terapeutycznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025032013423376e5c.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/membranous-nephropathy-model-17301407082144768.html</loc>
<image:image>
<image:title>Opracowywanie leków na rzecz postępującej nefropatii błoniastej (MN): platforma modelowa małpy Cynomolgus firmy Prisys Biotech</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacokinetics-of-inhaled-drugs-17301407389082624.html</loc>
<image:image>
<image:title>Farmakokinetyka leków wziewnych: zmiana paradygmatu z narażenia ogólnoustrojowego na narażenie płucne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/animal-models-for-womens-health-17301407134901248.html</loc>
<image:image>
<image:title>Prisys Biotech: modele zwierzęce w terapii zdrowia kobiet</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/world-obesity-day-nhp-metabolic-models-17301407383184384.html</loc>
<image:image>
<image:title>Światowy Dzień Otyłości|Prisys Biotech NHP Modele metaboliczne: zasilanie rozwoju terapii przeciw otyłości nowej generacji</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025030417050873614.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-s-cynomolgus-monkey-psoriasis-m-17301407186281472.html</loc>
<image:image>
<image:title>Prisys Biotech's Cynomolgus Monkey łuszczycy Model: Postępowanie przedkliniczna ocena farmakodynamiki</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202502280925537e8ce.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/integration-of-pharmacokinetics-and-pharmacody-17301406923793408.html</loc>
<image:image>
<image:title>Integracja farmakokinetyki i farmakodynamiki w opracowywaniu leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2025022110272438f73.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/on-demand-webinar-mri-ced-nhp-17888378840179712.html</loc>
<image:image>
<image:title>Seminarium internetowe na-żądanie|Most precyzyjny: MRI-CED pod kontrolą i możliwe do przetłumaczenia modele NHP do podawania leków do OUN</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202604301806570fdec.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/what-does-proof-of-concept-poc-in-drug-devel-17301407239676928.html</loc>
<image:image>
<image:title>Co tak naprawdę potwierdza dowód koncepcji (PoC) w opracowywaniu leków?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/animal-models-challenges-and-applications-in-17301406951760896.html</loc>
<image:image>
<image:title>Modele zwierzęce|Wyzwania i zastosowania w opracowywaniu modelu bólu</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonclinical-pharmacodynamic-research-17301407292417024.html</loc>
<image:image>
<image:title>Niekliniczne badania farmakodynamiczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/selecting-the-ideal-non-human-primate-for-toxi-17245402588587008.html</loc>
<image:image>
<image:title>Wybór idealnego naczelnego nie-człowieka do badań toksykologicznych: makak cynomolgus, makak rezus i marmozeta</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/rtimri-for-parkinsons-disease-81142029.html</loc>
<image:image>
<image:title>Terapia celowana w chorobie Parkinsona: przełom w-MRI w czasie rzeczywistym-przeszczepianiu komórek macierzystych pod kontrolą</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/systemic-lupus-erythematosus-sle-and-the-rol-17301406954791936.html</loc>
<image:image>
<image:title>Toczeń rumieniowaty układowy (SLE) i rola modeli zwierzęcych w rozwoju terapeutycznym</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-human-primate-model-for-rheumatoid-arthrit-17301407070807040.html</loc>
<image:image>
<image:title>Nie-ludzki model naczelnych dla reumatoidalnego zapalenia stawów (RA)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250117153412b3280.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/animal-brain-stereotactic-instruments-17301406891648000.html</loc>
<image:image>
<image:title>Instrumenty stereotaktyczne mózgu zwierząt oparte na trójwymiarowych układach współrzędnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250115133928772c1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/animal-models-for-in-vivo-testing-1-establi-17301407440462848.html</loc>
<image:image>
<image:title>Modele zwierzęce do badań in vivo (1): ustalenie i klasyfikacja</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/potential-routes-for-biologics-to-brain-84033127.html</loc>
<image:image>
<image:title>Odkrywanie potencjalnych dróg przedostawania się substancji biologicznych do mózgu</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advancing-rheumatoid-arthritis-ra-research-w-84034837.html</loc>
<image:image>
<image:title>Postęp w badaniach nad reumatoidalnym zapaleniem stawów (RZS) z wykorzystaniem modeli naczelnych innych niż ludzie</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20250102143547c190f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/animal-models-for-atopic-dermatitis-84033132.html</loc>
<image:image>
<image:title>Badanie modeli zwierzęcych pod kątem skuteczności leku na atopowe zapalenie skóry</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-critical-role-of-animal-models-in-human-di-84033130.html</loc>
<image:image>
<image:title>Krytyczna rola modeli zwierzęcych w badaniach nad chorobami człowieka</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202412271723592a539.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/parkin-gene-deficiency-monkey-model-reveals-ne-84033174.html</loc>
<image:image>
<image:title>Model małpy z niedoborem genu Parkina ujawnia nowe mechanizmy i cele terapeutyczne w leczeniu choroby Parkinsona</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonclinical-drug-development-guide-toxicity-84033186.html</loc>
<image:image>
<image:title>Przewodnik po opracowywaniu leków nieklinicznych: badania toksyczności ogólnej ostrej, podostrej, podprzewlekłej i przewlekłej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20241220112548bfcff.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nasal-to-brain-n2b-drug-delivery-84033138.html</loc>
<image:image>
<image:title>Innowacyjne dostarczanie leku przez nos do mózgu (N2B): omijanie bariery krew-mózg</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202412161319158371d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/minipig-as-nonclinical-large-animal-84033199.html</loc>
<image:image>
<image:title>Szanse i wyzwania związane ze świnkami miniaturowymi jako nieklinicznym gatunkiem dużych zwierząt</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/drug-delivery-strategies-for-brain-diseases-83021901.html</loc>
<image:image>
<image:title>Strategie dostarczania leków na choroby mózgu</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/real-time-intraoperative-mri-navigation-suppo-83020305.html</loc>
<image:image>
<image:title>Śródoperacyjna nawigacja MRI w-czasie rzeczywistym: wsparcie zatwierdzenia przez FDA pierwszej terapii genowej w leczeniu niedoboru AADC</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/ocular-toxicity-studies-of-eye-drops-drug-exp-83020308.html</loc>
<image:image>
<image:title>Badania toksyczności kropli do oczu: narażenie na leki i ocena bezpieczeństwa</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-establishes-cynomolgus-monkey-p-82713124.html</loc>
<image:image>
<image:title>Prisys Biotech ustanawia model łuszczycy makaka jawajskiego w celu przyspieszenia opracowywania leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/comprehensive-non-human-primate-models-for-ren-82713120.html</loc>
<image:image>
<image:title>Kompleksowe modele naczelnych innych niż ludzie do badań nad chorobami nerek przeprowadzone przez Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/comprehensive-preclinical-safety-evaluation-of-82713115.html</loc>
<image:image>
<image:title>Kompleksowa przedkliniczna ocena bezpieczeństwa przeciwciał-koniugatów leków (ADC) u naczelnych-nie będących ludźmi</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacokinetics-evaluation-of-antibody-drug-c-82713122.html</loc>
<image:image>
<image:title>Ocena farmakokinetyki przeciwciał-koniugatów leków (ADC) u-naczelnych ludzi</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacodynamics-evaluation-of-adcs-82713117.html</loc>
<image:image>
<image:title>Ocena farmakodynamiki ADC</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/understanding-the-dmpk-of-adc-drugs-82724903.html</loc>
<image:image>
<image:title>Zrozumienie DMPK leków ADC</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/progress-in-the-development-of-nucleic-acid-dr-82713121.html</loc>
<image:image>
<image:title>Postęp w rozwoju leków zawierających kwasy nukleinowe i możliwości badawcze Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advances-in-mrna-pulmonary-delivery-systems-an-82395261.html</loc>
<image:image>
<image:title>Postępy w systemach dostarczania do płuc mRNA i innowacyjnych usługach Prisys biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/2024-nobel-prize-in-physiology-or-medicine-82713140.html</loc>
<image:image>
<image:title>Dlaczego Nagroda Nobla w dziedzinie fizjologii lub medycyny w 2024 r. została przyznana tym dwóm naukowcom, którzy badali mikroRNA?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacokinetic-pk-considerations-for-centra-82713116.html</loc>
<image:image>
<image:title>Względy farmakokinetyczne (PK) dotyczące leków stosowanych w ośrodkowym układzie nerwowym (OUN).</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advancements-in-cns-research-ced-imri-79656490.html</loc>
<image:image>
<image:title>Postępy w badaniach nad OUN:-kompatybilny system wstrzykiwania mózgu do mózgu i technologia CED firmy Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818092955a6cca.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cynomolgus-monkey-mcao-model-81142031.html</loc>
<image:image>
<image:title>Postęp w innowacjach terapeutycznych w zakresie krwawień i krzepnięcia za pomocą modelu MCAO małpy Cynomolgus</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202409241700121ed48.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/dmpk-evaluation-of-central-nervous-system-cns-81142025.html</loc>
<image:image>
<image:title>Ocena DMPK leków na ośrodkowy układ nerwowy (OUN).</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/animal-models-of-human-diseases-81142020.html</loc>
<image:image>
<image:title>Zwierzęce modele chorób ludzkich</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/innovations-in-pain-evaluation-ai-driven-beha-81142022.html</loc>
<image:image>
<image:title>Innowacje w ocenie bólu:-analiza behawioralna oparta na sztucznej inteligencji</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/china-experimental-monkey-industry-81142400.html</loc>
<image:image>
<image:title>Historia, obecny stan, wyzwania i możliwości chińskiego eksperymentalnego przemysłu małp</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/human-disease-animal-models-81142019.html</loc>
<image:image>
<image:title>Modele zwierzęce chorób ludzkich: kluczowe narzędzie postępu badań biomedycznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-importance-of-preclinical-pharmacodynamics-81142024.html</loc>
<image:image>
<image:title>Znaczenie farmakodynamiki przedklinicznej w opracowywaniu leków|Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608180930355ea9f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/intranasal-administration-in-animal-studies-81142021.html</loc>
<image:image>
<image:title>Podawanie donosowe w badaniach na zwierzętach</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081809304573eca.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/revolutionizing-cns-drug-development-prisys-b-79419311.html</loc>
<image:image>
<image:title>Rewolucja w opracowywaniu leków na OUN: PRISYS Biotech wprowadza technologię IMRI</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20240729151529d56e9.png</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/convection-enhanced-delivery-81142018.html</loc>
<image:image>
<image:title>Postęp medycyny precyzyjnej: konwekcja-Technologia ulepszonego dostarczania (CED) firmy Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818093109a5b18.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cynomolgus-monkey-chronic-kidney-disease-model-81142023.html</loc>
<image:image>
<image:title>Model przewlekłej choroby nerek makaka jawajskiego (CKD) firmy Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20240820104326c1ab2.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonclinical-safety-evaluation-of-ocular-drug-d-79537570.html</loc>
<image:image>
<image:title>Niekliniczna ocena bezpieczeństwa podawania leków do oka przy użyciu makaków jawajskich</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081809313004e65.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/compartment-pk-model-81142026.html</loc>
<image:image>
<image:title>Zrozumienie modeli przedziałowych i niekompartmentowych-w farmakokinetyce</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advanced-cns-delivery-techniques-in-cynomolgus-81142402.html</loc>
<image:image>
<image:title>Zaawansowane techniki dostarczania do OUN u małp Cynomolgus: przyspieszenie rozwoju leków oligonukleotydowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818093209f5a1f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/reducing-the-use-of-nonhuman-primates-in-noncl-79537574.html</loc>
<image:image>
<image:title>Ograniczanie wykorzystania naczelnych innych niż ludzie w nieklinicznych ocenach bezpieczeństwa: perspektywy FDA i przemysłu</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818093218cb9d5.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/lcms-preclinical-bioanalysis-of-lnp-based-gene-79537600.html</loc>
<image:image>
<image:title>Przedkliniczna bioanaliza LCMS leków do terapii genowej na bazie LNP-</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818093228e8ded.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/mrna-based-therapies-past-79537586.html</loc>
<image:image>
<image:title>Terapie oparte na MRNA-: przeszłość</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081809332814450.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pk-strategies-of-pdc-79537553.html</loc>
<image:image>
<image:title>Strategie badań farmakokinetycznych peptydów-koniugatów leków (PDC)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818093337d1e36.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-role-of-aav-in-gene-therapy-immune-respon-79537590.html</loc>
<image:image>
<image:title>Rola AAV w terapii genowej: reakcje immunologiczne i toksyczność</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608180933456edfc.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/optimized-nonclinical-immunogenicity-evaluatio-79537596.html</loc>
<image:image>
<image:title>Zoptymalizowane strategie oceny nieklinicznej immunogenności</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818093356b38f2.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacodynamic-pd-evaluation-of-gene-therap-79537593.html</loc>
<image:image>
<image:title>Ocena farmakodynamiczna (PD) terapii genowej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081809344882063.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacokinetics-and-bioanalysis-of-oligonucle-79537582.html</loc>
<image:image>
<image:title>Farmakokinetyka i bioanaliza leków oligonukleotydowych-(1)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608180935436ab59.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacokinetics-and-bioanalysis-of-oligonucle-79537598.html</loc>
<image:image>
<image:title>Farmakokinetyka i bioanaliza leków oligonukleotydowych: charakterystyka farmakokinetyki wchłaniania i osocza (PK)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081809363714d7b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/factors-to-consider-for-the-immunogenicity-of-79537594.html</loc>
<image:image>
<image:title>Czynniki, które należy wziąć pod uwagę przy immunogenności leków oligonukleotydowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081809375929690.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/mrna-a-powerful-and-versatile-tool-for-fighti-79537603.html</loc>
<image:image>
<image:title>MRNA: potężne i wszechstronne narzędzie do zwalczania chorób-Prisys-Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081809383817f03.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/chinese-scientists-offers-new-strategies-to-re-79537583.html</loc>
<image:image>
<image:title>Chińscy naukowcy oferują nowe strategie odwracania głównych objawów choroby Parkinsona</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818094028d7d16.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotechnology-novel-lipid-nanoparticle-79537575.html</loc>
<image:image>
<image:title>Prisys Biotechnology: nowe nanocząsteczki lipidowe do dostarczania MRNA u naczelnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-importance-of-translational-medicine-resea-79537569.html</loc>
<image:image>
<image:title>Znaczenie badań medycyny translacyjnej od badań podstawowych do badań klinicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-main-factors-considered-in-woe-analysis-79537591.html</loc>
<image:image>
<image:title>Główne czynniki brane pod uwagę w analizie WOE</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-to-deliver-biologics-to-the-brain-79537587.html</loc>
<image:image>
<image:title>Jak dostarczyć substancje biologiczne do mózgu?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-drugs-move-and-change-in-our-bodies-a-bri-79537564.html</loc>
<image:image>
<image:title>Jak leki poruszają się i zmieniają w naszych ciałach: krótkie wprowadzenie do farmakokinetyki</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-to-develop-new-drugs-faster-and-safer-a-g-79537572.html</loc>
<image:image>
<image:title>Jak szybciej i bezpieczniej opracowywać nowe leki: przewodnik po przedklinicznych badaniach DMPK</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/group-housing-guidelines-for-laboratory-monkey-79537579.html</loc>
<image:image>
<image:title>Wytyczne dotyczące grupowego trzymania małp laboratoryjnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-vital-role-of-experimental-monkeys-in-adva-79537567.html</loc>
<image:image>
<image:title>Istotna rola eksperymentalnych małp w postępie badań naukowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/understanding-macaca-fascicularis-cynomolgus-79537595.html</loc>
<image:image>
<image:title>Zrozumienie Macaca Fascicularis (małpy Cynomolgus): Kluczowa charakterystyka i wkład w badania biomedyczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/revolutionizing-metabolic-disease-treatment-a-79537566.html</loc>
<image:image>
<image:title>Rewolucyjne leczenie chorób metabolicznych: postępy i wyzwania w opracowywaniu leków peptydowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-to-evaluate-the-safety-of-skin-products-be-79537565.html</loc>
<image:image>
<image:title>Jak ocenić bezpieczeństwo produktów do pielęgnacji skóry przed badaniami klinicznymi?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-significant-role-of-experimental-monkeys-i-79537584.html</loc>
<image:image>
<image:title>Znacząca rola eksperymentalnych małp w opracowywaniu innowacyjnych leków: spojrzenie na firmę od środka</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/liver-toxicity-as-a-key-concern-for-sirna-drug-79537576.html</loc>
<image:image>
<image:title>Toksyczność wątroby jako kluczowy problem w przypadku leków siRNA: wszechstronna analiza Specyficzność celu:-miecz obosieczny siRNA</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advancing-sirna-therapeutics-overcoming-chall-79537558.html</loc>
<image:image>
<image:title>Postęp w terapii SiRNA: pokonywanie wyzwań związanych z opracowywaniem leków</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/application-prospects-of-gene-drugs-based-on-l-79537556.html</loc>
<image:image>
<image:title>Perspektywy zastosowań leków genowych opartych na nanocząsteczkach lipidów</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/key-points-in-designing-strategies-for-non-79537580.html</loc>
<image:image>
<image:title>Kluczowe punkty w projektowaniu strategii-badań nieklinicznych na młodych zwierzętach</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/insight-into-the-sensory-and-behavioral-traits-79537581.html</loc>
<image:image>
<image:title>Wgląd w cechy sensoryczne i behawioralne-naczelnych (NHP)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonclinical-study-evaluation-q-a-79537588.html</loc>
<image:image>
<image:title>Pytania i odpowiedzi dotyczące oceny badania nieklinicznego</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/significance-principles-and-requirements-of-79537605.html</loc>
<image:image>
<image:title>Znaczenie, zasady i wymagania badań farmakologicznych dotyczących bezpieczeństwa</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-to-evaluate-preclinical-pharmacological-ef-79537557.html</loc>
<image:image>
<image:title>Jak ocenić przedkliniczną skuteczność farmakologiczną?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/reflections-on-non-clinical-pharmacology-studi-79537549.html</loc>
<image:image>
<image:title>Refleksje na temat-nieklinicznych badań farmakologicznych i oceny leków leczących-alkoholowe stłuszczeniowe zapalenie wątroby (NASH)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advancing-cns-and-cgt-research-prisys-biotech-79537559.html</loc>
<image:image>
<image:title>Postęp w badaniach nad CNS i CGT: Prisys Biotechnologies</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-human-primate-cerebrospinal-fluid-collecti-79537568.html</loc>
<image:image>
<image:title>Wytyczne dotyczące pobierania płynu mózgowo-rdzeniowego-od naczelnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/considerations-for-interpreting-clinical-patho-79537573.html</loc>
<image:image>
<image:title>Rozważania dotyczące interpretacji danych dotyczących patologii klinicznej u-naczelnych (NHP) i psów</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/integrating-cns-safety-evaluation-into-79537547.html</loc>
<image:image>
<image:title>​​​​​​​Włączenie oceny bezpieczeństwa OUN do ogólnych badań toksykologicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818092240ecd59.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-to-conduct-preclinical-pharmacology-toxico-79537585.html</loc>
<image:image>
<image:title>Jak przeprowadzić przedkliniczną ocenę farmakologiczną/toksykologiczną ADC?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/adme-insights-for-oligonucleotide-drugs-79537571.html</loc>
<image:image>
<image:title>Spostrzeżenia ADME dotyczące leków oligonukleotydowych (1) - Wchłanianie, dystrybucja</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/adme-insights-for-oligonucleotide-drugs-79537563.html</loc>
<image:image>
<image:title>Spostrzeżenia ADME dotyczące leków oligonukleotydowych (2) - Metabolizm i wydalanie</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/preclinical-animal-studies-1-animal-specie-79537548.html</loc>
<image:image>
<image:title>Przedkliniczne badania na zwierzętach (1) - Gatunki zwierząt</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/clinical-pathology-data-interpretation-challen-79537554.html</loc>
<image:image>
<image:title>Wyzwania i strategie interpretacji danych z zakresu patologii klinicznej w badaniach przedklinicznych psów i naczelnych-innych niż ludzie</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/preclinical-animal-studies-2-routes-and-vo-79537578.html</loc>
<image:image>
<image:title>Przedkliniczne badania na zwierzętach (2) - Drogi i objętości podawania</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/mrna-based-therapies-present-79537599.html</loc>
<image:image>
<image:title>Terapie oparte-MRNA: obecne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/mrna-based-therapies-future-and-challenges-79537597.html</loc>
<image:image>
<image:title>Terapie oparte-MRNA: przyszłość i wyzwania</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/brief-introduction-about-biological-analysis-o-79537592.html</loc>
<image:image>
<image:title>Krótkie wprowadzenie na temat analizy biologicznej terapii genowej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/cynomolgus-monkey-in-ophthalmic-drug-research-79419314.html</loc>
<image:image>
<image:title>Małpa Cynomolgus w badaniach leków okulistycznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-nhp-models-immunology-inflammatio-79419312.html</loc>
<image:image>
<image:title>Badania translacyjne i krzyżowe-Badania reaktywne z modelami immunologii i zapalenia NHP firmy Prisys</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-na-ve-nhps-in-preclinical-trials-a-cost-e-79198849.html</loc>
<image:image>
<image:title>Nie-naiwni NHP w badaniach przedklinicznych:-efektywne rozwiązanie pod względem kosztów autorstwa Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-asthma-model-79198846.html</loc>
<image:image>
<image:title>Model astmy NHP: wzmocnienie przedklinicznych badań skuteczności leków dzięki Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/advancing-immunology-and-inflammation-research-79198848.html</loc>
<image:image>
<image:title>Postęp w badaniach nad immunologią i stanami zapalnymi przy użyciu modeli makaków jawajskich - Prisys Biotechnologies</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/direct-delivery-of-oligonucleotide-drugs-to-th-79198845.html</loc>
<image:image>
<image:title>Bezpośrednie dostarczanie leków oligonukleotydowych do OUN i częste zmiany histopatologiczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/intra-cerebrovascular-stroke-ich-model-prisys-79198847.html</loc>
<image:image>
<image:title>Model-udaru mózgu (ICH) firmy Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-clinical-pharmacodynamics-research-an-ess-75167423.html</loc>
<image:image>
<image:title>Niekliniczne badania farmakodynamiczne: istotny aspekt w opracowywaniu leków siRNA</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/mri-guided-large-animal-central-nervous-system-77715757.html</loc>
<image:image>
<image:title>MRI-Precyzyjna lokalizacja i dostarczanie systemu centralnego układu nerwowego dużych zwierząt pod kontrolą systemu w Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2024042910594482ea8.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/innovative-solutions-for-advancing-respiratory-77062059.html</loc>
<image:image>
<image:title>Innowacyjne rozwiązania dla postępu w terapii oddechowej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202404261311431ebfc.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-advancing-animal-experimentation-throu-74795134.html</loc>
<image:image>
<image:title>Prisys: Postęp w eksperymentach na zwierzętach poprzez badania nad makakami cynomolgus</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081810523468f50.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-achieves-full-accreditation-from-aaalac-76181606.html</loc>
<image:image>
<image:title>Prisys uzyskuje pełną akredytację od AAALAC International: kamień milowy w zapewnianiu wysokich standardów opieki nad zwierzętami laboratoryjnymi.</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081810504717414.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/elevating-nucleic-acid-therapeutics-through-cu-74673455.html</loc>
<image:image>
<image:title>Udoskonalenie terapii kwasami nukleinowymi poprzez-nowoczesne modele naczelnych Prisys Biotech</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181049206508e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/revolutionizing-cns-drug-delivery-prisys-and-74170651.html</loc>
<image:image>
<image:title>Rewolucja w dostarczaniu leków do OUN: Prisys i obietnica wstrzyknięcia dokanałowego</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nonhuman-primate-study-newsletter-2024-q-75167422.html</loc>
<image:image>
<image:title>Biuletyn Prisys Biotech z I kwartału 2024 r. - Twój niezawodny specjalista ds. badań nad naczelnymi niebędącymi ludźmi</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2024022009580247f09.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-ultrasound-guided-liver-biopsy-enhances-ma-73541852.html</loc>
<image:image>
<image:title>Jak ultrasonografia-Biopsja wątroby pod kontrolą poprawia skuteczność badań makaków-</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818104547ef326.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/guidelines-for-lifetime-use-of-nonhuman-primat-73541853.html</loc>
<image:image>
<image:title>Wytyczne dotyczące dożywotniego wykorzystywania naczelnych innych niż ludzie w badaniach biomedycznych: perspektywa biotechnologii Prisys</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181046546955c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/non-human-primates-a-brief-introduction-to-th-73020311.html</loc>
<image:image>
<image:title>Naczelne-inne niż ludzie: krótkie wprowadzenie do ich cech biologicznych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818104755a1151.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/exhibition-review-prisys-biotech-shines-at-t-72678162.html</loc>
<image:image>
<image:title>Przegląd wystawy|Prisys Biotech błyszczy na dorocznym spotkaniu Amerykańskiego Towarzystwa Neuronauki (SfN 2023)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202311211050557965049.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/meet-prisys-biotech-at-the-society-for-neurosc-72321881.html</loc>
<image:image>
<image:title>Poznaj Prisys Biotech na dorocznym spotkaniu Towarzystwa Neuronauki (SfN 2023)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202311071007243112725.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/world-stroke-day-focus-on-ischemic-stroke-an-72321882.html</loc>
<image:image>
<image:title>Światowy Dzień Udaru Mózgu|Skoncentruj się na modelach zwierzęcych udaru niedokrwiennego i farmakologii</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-invites-you-to-attend-sapa-chin-72321877.html</loc>
<image:image>
<image:title>Prisys Biotech zaprasza na doroczne spotkanie SAPA-China w 2023 r</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202310271316191263008.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/world-alzheimer-s-day-the-challenges-and-sol-72321879.html</loc>
<image:image>
<image:title>Światowy Dzień Alzheimera|Wyzwania i rozwiązania dotyczące opracowywania leków na AD</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-s-cynomolgus-macaque-animal-mod-72321878.html</loc>
<image:image>
<image:title>Model zwierzęcy makaka Cynomolgus firmy Prisys Biotech pomaga w opracowywaniu nowych leków przeciwzakrzepowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-providing-high-quality-animal-experime-70974864.html</loc>
<image:image>
<image:title>Prisys: świadczenie-wysokiej jakości usług w zakresie eksperymentów na zwierzętach w zakresie nowego przeciwciała przeciwko-czynnikowi krzepnięcia XI BJTJ-1837</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/method-for-establishing-a-cynomolgus-monkey-mo-70974862.html</loc>
<image:image>
<image:title>Metoda ustalenia modelu hipertriglicerydemii u małpy Cynomolgus i jej zastosowanie</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacology-main-parameters-and-significance-70974865.html</loc>
<image:image>
<image:title>Farmakologia: główne parametry i znaczenie farmakokinetyki (PK)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/preclinical-pharmacology-evaluation-of-oncolyt-70974863.html</loc>
<image:image>
<image:title>Przedkliniczna ocena farmakologiczna leków zawierających wirusy onkolityczne</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/0-70974867.html</loc>
<image:image>
<image:title>Jak leki zawierające małe kwasy nukleinowe mogą zmienić sposób leczenia chorób OUN: spostrzeżenia Prisys Biotechnology, dostawcy modeli chorób NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/pharmacokinetics-research-strategies-and-case-70974866.html</loc>
<image:image>
<image:title>Farmakokinetyka, strategie badawcze i studia przypadków leków peptydowych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/key-research-points-of-adc-drug-pk-69655381.html</loc>
<image:image>
<image:title>Kluczowe punkty badawcze ADC Drug PK</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotechnology-a-leader-in-nhp-cns-dise-69654509.html</loc>
<image:image>
<image:title>Prisys Biotechnology: Lider platformy badawczej NHP do modelowania chorób OUN</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202307252159358927114.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-to-lose-weight-and-control-diabetes-with-g-69309322.html</loc>
<image:image>
<image:title>Jak schudnąć i kontrolować cukrzycę dzięki produktom GLP-1</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181233398a12e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-china-monkey-help-to-conduct-preclinical-r-69309296.html</loc>
<image:image>
<image:title>Jak China Monkey pomaga w prowadzeniu badań przedklinicznych?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818124638529d2.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/what-is-the-efficiency-of-rnai-69309313.html</loc>
<image:image>
<image:title>Jaka jest wydajność RNAi?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/large-animal-experiment-public-service-platfor-69309398.html</loc>
<image:image>
<image:title>Platforma usług publicznych Prisys Biotech do eksperymentów na dużych zwierzętach: tanie-i wysoko{1}}wydajne rozwiązanie do eksperymentów na dużych zwierzętach</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-aav-gene-therapy-can-save-your-vision-the-69046375.html</loc>
<image:image>
<image:title>Jak terapia genowa AAV może ocalić Twój wzrok: najnowsze odkrycia z badań na-ludzkich naczelnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-showcases-non-human-primate-mod-69045110.html</loc>
<image:image>
<image:title>Prisys Biotech prezentuje platformę-modeli naczelnych innych niż ludzie na dorocznym spotkaniu Japońskiego Towarzystwa Toksykologicznego</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202306272201578501988.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-promising-future-of-aav-gene-therapy-in-no-69048887.html</loc>
<image:image>
<image:title>Obiecująca przyszłość terapii genowej AAV u-naczelnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/what-are-lipid-nanoparticles-for-gene-therapy-69045589.html</loc>
<image:image>
<image:title>Jakie są nanocząsteczki lipidowe do terapii genowej?</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-invites-you-to-participate-in-t-69046334.html</loc>
<image:image>
<image:title>Prisys Biotech zaprasza do udziału w 50. dorocznym spotkaniu Japońskiego Towarzystwa Toksykologicznego (JSOT)</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202306160930293342952.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/immunotoxicity-test-drug-safety-evaluation-pr-69046148.html</loc>
<image:image>
<image:title>Test immunotoksyczności, ocena bezpieczeństwa leku-PRISYS BIOTECH</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/an-optimal-animal-model-of-ischemic-stroke-est-68306382.html</loc>
<image:image>
<image:title>Optymalny model zwierzęcy udaru niedokrwiennego ustalony za pomocą cyfrowej angiografii subtrakcyjnej-Sterowane autologiczne skrzepliny u małp Cynomolgus</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202306051532328723304.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/why-you-should-care-about-non-human-primates-68113529.html</loc>
<image:image>
<image:title>Dlaczego warto interesować się-naczelnymi innymi niż ludzie w badaniach i rozwoju systemów dostarczania leków na bazie kwasu nukleinowego</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/2026081812460527f54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/meet-prisys-biotech-at-70th-jalas-68113527.html</loc>
<image:image>
<image:title>Poznaj Prisys Biotech na 70. JALAS 2023!</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202305232011515935612.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/gene-therapy-shines-with-new-approvals-for-rar-68113533.html</loc>
<image:image>
<image:title>Terapia genowa błyszczy dzięki nowym zatwierdzeniom dotyczącym rzadkich chorób</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818112227f0067.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/revolutionizing-drug-discovery-nhp-68113525.html</loc>
<image:image>
<image:title>Rewolucyjne odkrywanie leków: jak naczelne inne niż ludzie optymalizują badania przesiewowe siRNA w celu uzyskania szybszych i skuteczniejszych wyników</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n2026081811211728443.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/maximizing-sirna-pharmacology-efficiency-67544404.html</loc>
<image:image>
<image:title>Maksymalizacja efektywności farmakologii SiRNA w badaniach na naczelnych innych niż ludzie</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181110261d729.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/how-nonhuman-primates-can-revolutionize-sirna-67540587.html</loc>
<image:image>
<image:title>Jak naczelne niebędące ludźmi mogą zrewolucjonizować badania nad SiRNA: kompleksowy przewodnik</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181109402926c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/celebrating-world-day-for-laboratory-animals-67538900.html</loc>
<image:image>
<image:title>Obchody Światowego Dnia Zwierząt Laboratoryjnych: dlaczego Prisys angażuje się w promowanie zdrowia zwierząt naczelnych</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202304242046033664975.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/maximizing-crispr-cas9-research-efficiency-wit-67542399.html</loc>
<image:image>
<image:title>Maksymalizacja efektywności badań CRISPR/Cas9 przy użyciu modeli naczelnych innych niż ludzie</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818110815e127c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/unleashing-the-therapeutic-potential-67562106.html</loc>
<image:image>
<image:title>Uwolnienie potencjału terapeutycznego: dlaczego inwestowanie w leki zawierające kwasy nukleinowe jest przyszłością medycyny</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181107339a708.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/unlocking-the-potential-of-nonhuman-primates-67541547.html</loc>
<image:image>
<image:title>Odblokowanie potencjału naczelnych innych niż ludzie w usprawnianiu odkrywania celów leków w terapii genowej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181106513ac69.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/world-parkinsons-disease-day-67546212.html</loc>
<image:image>
<image:title>Unite For Parkinson's: Łączenie rąk w celu podniesienia świadomości w Światowym Dniu Choroby Parkinsona</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202304111648126878455.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/nhp-effectively-in-gene-therapy-67542400.html</loc>
<image:image>
<image:title>Jak skutecznie wykorzystywać-naczelne inne niż ludzie w ocenie bezpieczeństwa terapii genowej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818110521065c0.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/gene-therapy-toxicology-66275452.html</loc>
<image:image>
<image:title>Badania toksykologiczne terapii genowej z naczelnym Nonhuam</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n202608181102082f663.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/dmpk-study-for-gene-therapy-66120700.html</loc>
<image:image>
<image:title>Kompleksowy przewodnik po przeprowadzaniu badania DMPK pod kątem terapii genowej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818110117c7822.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/gene-therapy-nhp-model-66118670.html</loc>
<image:image>
<image:title>Rewolucyjne badania medyczne: przełomy w terapii genowej w modelach chorób naczelnych innych niż ludzie!</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818105650617bb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/top-10-popular-questions-related-to-gene-thera-66118677.html</loc>
<image:image>
<image:title>10 najpopularniejszych pytań związanych z terapią genową</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818105726b2641.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-biotech-non-human-primate-pharmacology-66118672.html</loc>
<image:image>
<image:title>Prisys Biotech: Farmakologia naczelnych nieludzkich-w terapii genowej</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818105536d2837.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/supporting-women-s-health-a-look-into-endomet-66118673.html</loc>
<image:image>
<image:title>Wspieranie zdrowia kobiet: spojrzenie na endometriozę</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202303080917443223214.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-sot2023-66118669.html</loc>
<image:image>
<image:title>PRISYS i Taichu Group współpracują przy wystawie SOT w 2023 roku</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202303101009207805940.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/do-we-need-further-studies-for-pain-assessment-66118666.html</loc>
<image:image>
<image:title>Czy potrzebujemy dalszych badań w celu oceny bólu? - NHP</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/39406/news/n20260818105333c5854.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/prisys-celebrating-world-wildlife-day-66118668.html</loc>
<image:image>
<image:title>Dołącz do nas w obchodach Światowego Dnia Dzikiej Przyrody</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202303031713469632535.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/the-construction-of-prisys-shanghai-nhp-r-d-ce-66119754.html</loc>
<image:image>
<image:title>Uruchamia centrum badawczo-rozwojowe Prisys Shanghai NHP, co stanowi kamień milowy w dziedzinie badań i rozwoju farmaceutycznego w Chinach</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202303081340054460581.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://pl.prisysbiotech.com/news/meetprisys-sot2023-66118667.html</loc>
<image:image>
<image:title>Meet Prisys @ Booth No. 1434 in The Upcoming SOT Conference | US-Roadshow</image:title>
<image:loc>https://pl.prisysbiotech.com/uploads/202339406/n202303031705254453292.jpg</image:loc>
</image:image>
</url>
</urlset>